The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease

被引:424
作者
Haffner, SM [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX USA
关键词
D O I
10.1016/j.amjcard.2005.11.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is accumulating evidence that inflammation is an important risk factor in cardiovascular disease (CVD). Elevated levels of the inflammatory marker high-sensitivity C-reactive protein (hs-CRP) are associated with increased risk for CVD, and diabetes mellitus. Adding hs-CRP to the definition of the metabolic syndrome has been shown to improve the prediction of CVD. Elevated hs-CRP levels may also be predictive of development of the metabolic syndrome. Current definitions of the metabolic syndrome differ, and cardiovascular risk appears to differ according to which component risk factors are present. Further studies are required to identify a widely accepted criterion for the syndrome that will optimally predict the risk of diabetes and CVD. It is possible that such a definition will include a measure of inflammation. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:3A / 11A
页数:9
相关论文
共 24 条
[1]   NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM ;
Haffner, SM .
DIABETES, 2003, 52 (05) :1210-1214
[2]  
[Anonymous], 2006, IDF CONSENSUS WORLDW
[3]   Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: Results of the andromeda study [J].
Betteridge, D ;
Gibson, M .
ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) :107-108
[4]   Effect of rosuvastatin and atorvastatin on CRP levels in patients with type 2 diabetes: Results from the Andromeda Study [J].
Betteridge, DJ ;
Gibson, JM ;
Sager, P .
ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) :102-102
[5]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]   Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes - The insulin resistance atherosclerosis study [J].
Festa, A ;
D'Agostino, R ;
Tracy, RP ;
Haffner, SM .
DIABETES, 2002, 51 (04) :1131-1137
[8]   Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion [J].
Festa, A ;
Hanley, AJG ;
Tracy, RP ;
D'Agostino, R ;
Haffner, SM .
CIRCULATION, 2003, 108 (15) :1822-1830
[9]   Chronic subclinical inflammation as part of the insulin resistance syndrome -: The Insulin Resistance Atherosclerosis Study (IRAS) [J].
Festa, A ;
D'Agostino, R ;
Howard, G ;
Mykkänen, L ;
Tracy, RP ;
Haffner, SM .
CIRCULATION, 2000, 102 (01) :42-47
[10]  
Gavin JR, 1997, DIABETES CARE, V20, P1183